Radiation Oncology

Immunotherapy   

Questions discussed in this category


One example of this scenario would be a patient receiving consolidative durvalumab after chemoRT for stage III NSCLC who develops a new peripheral lun...

How do you prescribe a steroid taper? If it is grade 2, would you keep them on low dose prednisone while continuing? When do you feel comfortable re-c...

Rate of pneumonitis was low in the PACIFIC trial but does it mirror the real world setting? We are seeing increased pneumonitis in our practice.

Do the results of the unplanned subset analysis of the PACIFIC trial showing no OS benefit in this population lean you away from consolidation?

In patients who have a mixed response or progression and are poor candidates for other systemic agents, would you consider consolidating the chest? Wo...

I recently saw a patient who had been treated with concurrent pembrolizumab-RT elsewhere. Is this an acceptable practice outside the setting of a clin...

These patients have been largely excluded from these trials.  What if the infection is well controlled?

If not what radiation fractionation regimen is preferred for otherwise good KPS patient? 

Is there any consensus regarding the optimal RT dose, fractionation, and timing to the best abscopal response? What is the optimal metastatic site to ...


Papers discussed in this category


Radiat Oncol, 2015 Apr 26

N Engl J Med, 2017 Nov 16

Lancet Oncol, 2017 Jul

Int J Radiat Oncol Biol Phys, 2017 Jun 1

JAMA Oncol,

N. Engl. J. Med., 2018 Sep 25

Future Oncol, 2019 Apr 25

Radiat Oncol, 2014 Sep 19

J Clin Oncol, 2018 Feb 13

Int. J. Radiat. Oncol. Biol. Phys., 2018 Apr 27

Int. J. Radiat. Oncol. Biol. Phys., 2016 Jul 15

Eur. Respir. J., 2018 Jan 04

Pract Radiat Oncol, 2017 Dec 08